SCHEMBL5773740

SCHEMBL5773740

Ic1ccc(/C=N/Nc2ccc(-c3cccnc3)cc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 10/20 0.53
MAPT P10636 9/20 0.53
SMN1; SMN2 Q16637 6/20 0.53
ALDH1A1 P00352 5/20 0.53
LMNA P02545 4/20 0.53
GFER P55789 2/20 0.53
TDP1 Q9NUW8 1/20 0.53
RAB9A P51151 10/20 0.52
NPC1 O15118 8/20 0.52
HDAC3 O15379 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC2 Q92769 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
MEN1 O00255 5/20 0.45
KMT2A Q03164 5/20 0.45
KDM4E B2RXH2 4/20 0.45
HSP90AA1 P07900 2/20 0.45
POLB P06746 2/20 0.45
NFKB1 P19838 2/20 0.45
NFKB2 Q00653 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5773744 1.00 GAA (0.53) GAAMAPTSMN1; SMN2ALDH1A1LMNA
SCHEMBL5775664 0.87 RAB9A (0.57) GAAMAPTSMN1; SMN2ALDH1A1LMNA
SCHEMBL5780650 0.82 MAPT (0.49) GAAMAPTSMN1; SMN2ALDH1A1LMNA
SCHEMBL5778977 0.78 MAPT (0.45) GAAMAPTSMN1; SMN2ALDH1A1LMNA
SCHEMBL5778974 0.78 MAPT (0.45) GAAMAPTSMN1; SMN2ALDH1A1LMNA
SCHEMBL5778611 0.78 RAB9A (0.68) GAAMAPTSMN1; SMN2ALDH1A1LMNA
SCHEMBL9467041 0.77 CYP2A6 (0.68) MAPTSMN1; SMN2ALDH1A1LMNAMEN1
SCHEMBL5778666 0.74 HDAC3 (0.42) GAAMAPTSMN1; SMN2ALDH1A1LMNA
SCHEMBL31429956 0.72 NOX1 (0.77) GAAMAPTSMN1; SMN2ALDH1A1LMNA
SCHEMBL3644281 0.71 CYP2A6 (0.58) ALDH1A1HDAC3HDAC1HDAC2HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060276433-A1 Hydrazone derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-12-07 US disclosed
EP-1612204-A1 HYDRAZONE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-01-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276433-A1 Hydrazone derivative APP, PRNP, HTT GAA 3175/4885MAPT 94/4885SMN1; SMN2 2146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.